Patents by Inventor Dennie Welch

Dennie Welch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10954202
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: March 23, 2021
    Assignee: AbbVie Inc.
    Inventors: Zhaoming Xiong, Jennifer M. Frost, Philip R. Kym, Xueqing Wang, Shuang Chen, Dennie Welch
  • Publication number: 20210009542
    Abstract: Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases, disorders and conditions favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 14, 2021
    Inventors: Zhaoming Xiong, Jennifer M. Frost, Philip R. Kym, Xueqing Wang, Shuang Chen, Dennie Welch
  • Publication number: 20170239212
    Abstract: Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including the treatment or prevention of viral infection. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in a low number of steps and with a high degree of substitution and specificity.
    Type: Application
    Filed: August 10, 2015
    Publication date: August 24, 2017
    Inventors: Gary E. KECK, Matthew B. KRAFT, Anh P. TRUONG, Carina C. SANCHEZ, Wei LI, Jonathan A. COVEL, Dennie WELCH, Yam POUDEL, Mark E. PETERSEN
  • Patent number: 9096550
    Abstract: Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in fewer steps and with a higher degree of substitution and specificity.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: August 4, 2015
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Gary E Keck, Matthew B Kraft, Anh P Truong, Carina C Sanchez, Wei Li, Jonathan A Covel, Dennie Welch, Yam Poudel
  • Publication number: 20110269713
    Abstract: Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing macrolactones. The methods permit the high-yield synthesis of macrolactones in fewer steps and with a higher degree of substitution and specificity.
    Type: Application
    Filed: October 14, 2010
    Publication date: November 3, 2011
    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Gary E. Keck, Matthew B. Kraft, Anh P. Truong, Carina C. Sanchez, Wei Li, Jonathan A. Covel, Dennie Welch, Yam Poudel